The course of COVID-19 infection and prolonged sneezing and nasal congestion in a patient using ixekizumab

Basit Öğe Kaydı
dc.authorid0000-0001-8604-022Xen_US
dc.contributor.authorGüder, Semih
dc.contributor.authorGüder, Hüsna
dc.date.accessioned2024-07-12T21:14:14Z
dc.date.available2024-07-12T21:14:14Z
dc.date.issued2021en_US
dc.departmentFakülteler, Tıp Fakültesien_US
dc.description.abstractWith the onset of the Coronavirus disease 2019 (COVID?19) pandemic, we had concerns about managing the treatments of the patients who received biological therapy. To share our experience, we described the clinical course of a patient with COVID?19 who used ixekizumab. A 46?year?old female patient with hypertension, bronchiectasis, allergic rhinitis, house dust allergy, chronic plaque?type psoriasis, and psoriatic arthritis with a positive QuantiFERON blood test used ixekizumab 160?mg, perindopril/indapamide combination, and received isoniazid for tuberculosis prophylaxis with a dose of 300?mg/day. She continued ixekizumab treatment for 6?months. After the last dose of the ixekizumab, the patient had complaints of mild fever (37.5°C) and coughing for 3?days. She contacted a person who had a positive polymerase chain reaction (PCR) 6?days ago for severe acute respiratory syndrome coronavirus 2 (SARS?CoV?2). The patient's nasopharyngeal swab PCR test was found to be positive for SARS?CoV?2. At admission, the patient's oxygen saturation was 98%, and her lung tomography had a bilateral ground?glass appearance. She was hospitalized in the infectious diseases service, and she began to receive favipiravir (1600?mg orally twice a day on the first day, and followed by 600?mg orally twice a day), enoxaparin sodium solution s.c. 60?mg/0.6 mL/day, and paracetamol 500?mg/day p.o. On the third day of the treatment, her fever decreased, and she had a complaint of mild shortness of breath. Favipiravir treatment was completed and stopped on the fifth day. At the end of the first week, the dyspnea was completely recovered, and the fever did not occur after discharge. After a week, symptoms of sneezing and nasal congestion started. Two SARS?CoV?2 nasopharyngeal swab samples repeated 30?days after the initial diagnosis yielded negative results. One ixekizumab dose was skipped, and the treatment continued 1?month later. The patient had not new psoriatic lesions, and joint complaints during and after the COVID 19 infection. The psoriasis area severity index (PASI) value of the patient, which was 11.8 when she started the ixekizumab treatment, was measured as 1.2 in the sixth week of the treatment. The PASI value did not change during and after the COVID?19 infection. Interleukin?17 (IL?17) was considered to promote viral persistence by inhibiting the apoptosis of virus?infected cells and to cause Th17?related cytokine storm syndrome. 1 In a recent study of the Italian psoriasis?biologics?COVID working group, the researchers thought that biological therapies could reduce the cytokine storm which may lead to multiorgan failure, ARDS, and death. 2 Therefore, inhibition of IL?17 may have contributed to the mild course of the disease in the present case.en_US
dc.identifier.citationGüder, S. ve Güder, H. (2021). The course of COVID-19 infection and prolonged sneezing and nasal congestion in a patient using ixekizumab. Dermatologic Therapy, Wiley Online. 34(2).en_US
dc.identifier.doi10.1111/dth.14894
dc.identifier.issn1529-8019
dc.identifier.issue2en_US
dc.identifier.pmid33599042en_US
dc.identifier.scopus2-s2.0-85101221925en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttps://pubmed.ncbi.nlm.nih.gov/33599042/
dc.identifier.urihttps://doi.prg/10.1111/dth.14894
dc.identifier.urihttps://hdl.handle.net/20.500.12415/4595
dc.identifier.volume34en_US
dc.identifier.wosWOS:000620554800001en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorGüder, Hüsna
dc.language.isoenen_US
dc.publisherWiley Onlineen_US
dc.relation.ispartofDermatologic Therapyen_US
dc.relation.publicationcategoryUluslararası Hakemli Dergide Makale - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmzKY08900
dc.titleThe course of COVID-19 infection and prolonged sneezing and nasal congestion in a patient using ixekizumaben_US
dc.typeLetter
dspace.entity.typePublication

Dosyalar

Koleksiyon

Tıp Fakültesi Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu